alendronate has been researched along with Liver Neoplasms in 7 studies
alendronic acid : A 1,1-bis(phosphonic acid) that is methanebis(phosphonic acid) in which the two methylene hydrogens are replaced by hydroxy and 3-aminopropyl groups.
Liver Neoplasms: Tumors or cancer of the LIVER.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Cohort studies reporting association between alendronate or bisphosphonate therapy including alendronate in patients with osteoporosis and risk of cancer were selected by two authors." | 8.91 | The carcinogenicity of alendronate in patients with osteoporosis: evidence from cohort studies. ( Chen, LX; Cheng, L; Feng, SQ; Li, YL; Ning, GZ; Wu, QL; Zhang, D; Zhang, TS; Zhou, ZR, 2015) |
| "Treatment of hepatocellular carcinoma (HCC) cell line with FTI-277 alone showed cell death in a time and dose dependent manner while in combination with alendronate, a synergistic apoptotic effect at 24 h was observed." | 7.88 | Alendronate and FTI-277 combination as a possible therapeutic approach for hepatocellular carcinoma: An in vitro study. ( Channa, IS; Hashim, Z; Ilyas, A; Zarina, S, 2018) |
| "Alendronate, a bisphosphonate compound, lowers serum calcium in patients with cancer-associated hypercalcemia through its inhibitory effect on bone resorption and as a result symptoms associated with hypercalcemia improve." | 7.70 | Effects of alendronate on bone metastases and hypercalcemia after surgery for hepatocellular carcinoma. ( Kinoshita, T; Matsumoto, T; Miyake, H; Ohnishi, T; Takeda, E; Tashiro, S; Terashima, Y; Yogita, S, 2000) |
| "Cohort studies reporting association between alendronate or bisphosphonate therapy including alendronate in patients with osteoporosis and risk of cancer were selected by two authors." | 4.91 | The carcinogenicity of alendronate in patients with osteoporosis: evidence from cohort studies. ( Chen, LX; Cheng, L; Feng, SQ; Li, YL; Ning, GZ; Wu, QL; Zhang, D; Zhang, TS; Zhou, ZR, 2015) |
| "Treatment of hepatocellular carcinoma (HCC) cell line with FTI-277 alone showed cell death in a time and dose dependent manner while in combination with alendronate, a synergistic apoptotic effect at 24 h was observed." | 3.88 | Alendronate and FTI-277 combination as a possible therapeutic approach for hepatocellular carcinoma: An in vitro study. ( Channa, IS; Hashim, Z; Ilyas, A; Zarina, S, 2018) |
| "Alendronate, a bisphosphonate compound, lowers serum calcium in patients with cancer-associated hypercalcemia through its inhibitory effect on bone resorption and as a result symptoms associated with hypercalcemia improve." | 3.70 | Effects of alendronate on bone metastases and hypercalcemia after surgery for hepatocellular carcinoma. ( Kinoshita, T; Matsumoto, T; Miyake, H; Ohnishi, T; Takeda, E; Tashiro, S; Terashima, Y; Yogita, S, 2000) |
| "The various features of carcinoid tumors metastasizing to the skeleton are briefly reviewed." | 1.31 | Case of an ivory vertebra. ( Ball, DW; Basaria, S; Belzberg, AJ; McCarthy, EF, 2000) |
| " The findings suggest that there is no pharmacodynamic advantage for continuous infusion of alendronate." | 1.31 | Pharmacokinetic and pharmacodynamic evaluation of intermittent versus continuous alendronate administration in rats. ( Golomb, G; Hoffman, A; Stepensky, D, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (42.86) | 29.6817 |
| 2010's | 4 (57.14) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ilyas, A | 2 |
| Hashim, Z | 2 |
| Channa, IS | 1 |
| Zarina, S | 2 |
| Chen, LX | 1 |
| Ning, GZ | 1 |
| Zhou, ZR | 1 |
| Li, YL | 1 |
| Zhang, D | 1 |
| Wu, QL | 1 |
| Zhang, TS | 1 |
| Cheng, L | 1 |
| Feng, SQ | 1 |
| Cheng, H | 1 |
| Liao, ZL | 1 |
| Ning, LH | 1 |
| Chen, HY | 1 |
| Wei, SS | 1 |
| Yang, XC | 1 |
| Guo, H | 1 |
| Basaria, S | 1 |
| McCarthy, EF | 1 |
| Belzberg, AJ | 1 |
| Ball, DW | 1 |
| Ohnishi, T | 1 |
| Takeda, E | 1 |
| Yogita, S | 1 |
| Miyake, H | 1 |
| Kinoshita, T | 1 |
| Terashima, Y | 1 |
| Matsumoto, T | 1 |
| Tashiro, S | 1 |
| Stepensky, D | 1 |
| Golomb, G | 1 |
| Hoffman, A | 1 |
1 review available for alendronate and Liver Neoplasms
| Article | Year |
|---|---|
The carcinogenicity of alendronate in patients with osteoporosis: evidence from cohort studies.
Topics: Alendronate; Bone Density Conservation Agents; Cohort Studies; Colorectal Neoplasms; Female; Humans; | 2015 |
6 other studies available for alendronate and Liver Neoplasms
| Article | Year |
|---|---|
Alendronate and FTI-277 combination as a possible therapeutic approach for hepatocellular carcinoma: An in vitro study.
Topics: Alendronate; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Carcinoma | 2018 |
Effects of 5'-azacytidine and alendronate on a hepatocellular carcinoma cell line: a proteomics perspective.
Topics: Alendronate; Apoptosis; Azacitidine; Biomarkers, Tumor; Carcinoma, Hepatocellular; Cell Line, Tumor; | 2015 |
Alendronate-anchored PEGylation of ceria nanoparticles promotes human hepatoma cell proliferation via AKT/ERK signaling pathways.
Topics: Alendronate; Animals; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Ce | 2017 |
Case of an ivory vertebra.
Topics: Alendronate; Alkaline Phosphatase; Biopsy; Bone Marrow; Carcinoid Tumor; Diagnosis, Differential; Di | 2000 |
Effects of alendronate on bone metastases and hypercalcemia after surgery for hepatocellular carcinoma.
Topics: Aged; Alendronate; Bone Neoplasms; Carcinoma, Hepatocellular; Female; Humans; Hypercalcemia; Liver N | 2000 |
Pharmacokinetic and pharmacodynamic evaluation of intermittent versus continuous alendronate administration in rats.
Topics: Alendronate; Animals; Bone Neoplasms; Bone Resorption; Calcium; Carcinoma 256, Walker; Drug Administ | 2002 |